Corbus Pharmaceuticals Holdings, INC DEF 14A proxy statements

Corbus Pharmaceuticals Holdings, Inc. is holding its Annual Meeting of Stockholders on May 13, 2026, to vote on key proposals including an increase in authorized shares for its 2024 Equity Compensation Plan.

Corbus Pharmaceuticals Holdings, Inc. has filed a definitive proxy statement with the SEC.

Corbus Pharmaceuticals Holdings will hold its annual meeting of stockholders virtually on May 15, 2025, to vote on director elections, auditor ratification, and executive compensation.

Corbus Pharmaceuticals has issued a supplement to its proxy statement clarifying voting standards for proposals and detailing amended employment agreements for its CEO and CFO.

Corbus Pharmaceuticals Holdings, Inc. has filed a definitive proxy statement with the SEC.

Corbus Pharmaceuticals Holdings is asking stockholders to approve the 2024 Equity Compensation Plan and authorize 2,000,000 shares for issuance.